Monty Montoya, President & CEO, delivered many updates on the company’s new take on corneal care to OIS@ASCRS. The start-up is evaluating tissue, preparing tissue for transplant, and managing the transportation logistics. Montoya introduced Sightline’s medical advisory board and educational faculty. He also introduced the company’s new product offerings include autologous serum tears secured in a partnership with Imprimis. In addition, Montoya revealed a partnership with Dr. Shigeru Kinoshita of Kyoto to employ his new endothelial cell therapy in corneal treatment. The company expects to raise a $30 million Series B in 2018.